Mount Yale Investment Advisors’s Definium Therapeutics DFTX Stock Holding History

Mount Yale Investment Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$535K	Buy	+11,382	New	+$281K	0.01%	757

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Mount Yale Investment Advisors's DFTX Position: Q2 2026 in Review

Mount Yale Investment Advisors opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 11,382 shares worth $535K. The stake represents 0.01% of the portfolio and ranks #757 among its holdings.

361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Mount Yale Investment Advisors held 11,382 shares of Definium Therapeutics worth $535K as of Q2 2026.
Definium Therapeutics was a new Mount Yale Investment Advisors position in Q2 2026.
Definium Therapeutics made up 0.01% of Mount Yale Investment Advisors's portfolio in Q2 2026, its #757 holding.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.